Classification of scaffold-hopping approaches.

The general goal of drug discovery is to identify novel compounds that are active against a preselected biological target with acceptable pharmacological properties defined by marketed drugs. Scaffold hopping has been widely applied by medicinal chemists to discover equipotent compounds with novel backbones that have improved properties. In this article we classify scaffold hopping into four major categories, namely heterocycle replacements, ring opening or closure, peptidomimetics and topology-based hopping. We review the structural diversity of original and final scaffolds with respect to each category. We discuss the advantages and limitations of small, medium and large-step scaffold hopping. Finally, we summarize software that is frequently used to facilitate different kinds of scaffold-hopping methods.

[1]  F. Totzke,et al.  N-substituted 2'-(aminoaryl)benzothiazoles as kinase inhibitors: hit identification and scaffold hopping. , 2009, Bioorganic & medicinal chemistry letters.

[2]  Peter Willett,et al.  Effectiveness of 2D fingerprints for scaffold hopping. , 2011, Future medicinal chemistry.

[3]  Darrell R. Abernethy,et al.  International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.

[4]  Vickie Tsui,et al.  Orally bioavailable antagonists of inhibitor of apoptosis proteins based on an azabicyclooctane scaffold. , 2009, Journal of medicinal chemistry.

[5]  J. Lutkenhaus,et al.  Bacterial cell division and the Z ring. , 1997, Annual review of biochemistry.

[6]  A. Hallberg,et al.  A selective AT2 receptor ligand with a gamma-turn-like mimetic replacing the amino acid residues 4-5 of angiotensin II. , 2004, Journal of medicinal chemistry.

[7]  M. J. Uddin,et al.  Design and synthesis of novel celecoxib analogues as selective cyclooxygenase-2 (COX-2) inhibitors: replacement of the sulfonamide pharmacophore by a sulfonylazide bioisostere. , 2003, Bioorganic & medicinal chemistry.

[8]  N. Ackerman,et al.  Anti-inflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor. , 1990, The Journal of pharmacology and experimental therapeutics.

[9]  James R Kiefer,et al.  The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part 2: the second clinical candidate having a shorter and favorable human half-life. , 2010, Bioorganic & medicinal chemistry letters.

[10]  A. Doherty,et al.  In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor. , 1997, The Journal of pharmacology and experimental therapeutics.

[11]  David S. Wishart,et al.  DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..

[12]  David R. Langley,et al.  MORPH: A New Tool for Ligand Design , 2010, J. Chem. Inf. Model..

[13]  Jason M. White,et al.  Behavioural effects of histamine and its antagonists: a review , 2004, Psychopharmacology.

[14]  W. Pitt,et al.  Heteroaromatic rings of the future. , 2009, Journal of medicinal chemistry.

[15]  Bin Chen,et al.  PubChem BioAssays as a data source for predictive models. , 2010, Journal of molecular graphics & modelling.

[16]  Ismael Zamora,et al.  SHOP: A Method For Structure‐Based Fragment and Scaffold Hopping , 2009, ChemMedChem.

[17]  Bin Chen,et al.  PubChem as a Source of Polypharmacology , 2009, J. Chem. Inf. Model..

[18]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.

[19]  P. Labute,et al.  Flexible alignment of small molecules. , 2001, Journal of medicinal chemistry.

[20]  P. Furet,et al.  Entry into a new class of protein kinase inhibitors by pseudo ring design. , 2008, Bioorganic & medicinal chemistry letters.

[21]  T. Torroba,et al.  Synthesis of benzodiazepine beta-turn mimetics by an Ugi 4CC/Staudinger/aza-Wittig sequence. Solving the conformational behavior of the Ugi 4CC adducts. , 2009, The Journal of organic chemistry.

[22]  L. Vassilev.  p53 Activation by small molecules: application in oncology. , 2005, Journal of medicinal chemistry.

[23]  Wolfgang Guba,et al.  Recent developments in de novo design and scaffold hopping. , 2008, Current opinion in drug discovery & development.

[24]  A. Hallberg,et al.  Design, synthesis, and incorporation of a beta-turn mimetic in angiotensin II forming novel pseudopeptides with affinity for AT1 and AT2 receptors. , 2006, Journal of medicinal chemistry.

[25]  M. Billah,et al.  Dual antagonists of platelet activating factor and histamine. Identification of structural requirements for dual activity of N-Acyl-4-(5,6-dihydro-11H-benzo [5,6]cyclohepta-[1,2-b]pyridin-11-ylidene)piperidines. , 1991, Journal of medicinal chemistry.

[26]  G. Schneider,et al.  Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening. , 2007, Journal of medicinal chemistry.

[27]  Jonas Boström,et al.  Scaffold hopping, synthesis and structure-activity relationships of 5,6-diaryl-pyrazine-2-amide derivatives: a novel series of CB1 receptor antagonists. , 2007, Bioorganic & medicinal chemistry.

[28]  Ruili Huang,et al.  The NCGC Pharmaceutical Collection: A Comprehensive Resource of Clinically Approved Drugs Enabling Repurposing and Chemical Genomics , 2011, Science Translational Medicine.

[29]  D. Dewitt,et al.  Cox-2-selective inhibitors: the new super aspirins. , 1999, Molecular pharmacology.

[30]  F. Allen.  The Cambridge Structural Database: a quarter of a million crystal structures and rising. , 2002, Acta crystallographica. Section B, Structural science.

[31]  M. Yamada,et al.  Novel spiropiperidine-based stearoyl-CoA desaturase-1 inhibitors: Identification of 1'-{6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-5-(trifluoromethyl)-3,4-dihydrospiro[chromene-2,4'-piperidine]. , 2010, Bioorganic & medicinal chemistry letters.

[32]  C. Hale,et al.  Direct Binding of FtsZ to ZipA, an Essential Component of the Septal Ring Structure That Mediates Cell Division in E. coli , 1997, Cell.

[33]  C. Hodge,et al.  A diazine heterocycle replaces a six-membered hydrogen-bonded array in the active site of scytalone dehydratase , 1993 .

[34]  A T Brünger,et al.  Three-dimensional structure of an angiotensin II-Fab complex at 3 A: hormone recognition by an anti-idiotypic antibody. , 1992, Science.

[35]  Robert J. Jilek,et al.  "Lead hopping". Validation of topomer similarity as a superior predictor of similar biological activities. , 2004, Journal of medicinal chemistry.

[36]  S. Lampel,et al.  The druggable genome: an update. , 2005, Drug discovery today.

[37]  Christian Sköld,et al.  Angiotensin II pseudopeptides containing 1,3,5-trisubstituted benzene scaffolds with high AT2 receptor affinity. , 2005, Journal of medicinal chemistry.

[38]  T. Ritchie,et al.  The impact of aromatic ring count on compound developability--are too many aromatic rings a liability in drug design? , 2009, Drug discovery today.

[39]  Brian K. Shoichet,et al.  ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..

[40]  J. Gierse,et al.  A Single Amino Acid Difference between Cyclooxygenase-1 (COX-1) and −2 (COX-2) Reverses the Selectivity of COX-2 Specific Inhibitors* , 1996, The Journal of Biological Chemistry.

[41]  David Fry,et al.  Utilizing peptide structures as keys for unlocking challenging targets. , 2006, Mini reviews in medicinal chemistry.

[42]  Y. Martin,et al.  Beyond QSAR: Lead Hopping to Different Structures , 2009 .

[43]  Qiang Zhang,et al.  Scaffold hopping through virtual screening using 2D and 3D similarity descriptors: ranking, voting, and consensus scoring. , 2006, Journal of medicinal chemistry.

[44]  Jie Wu,et al.  Optimization of triaryl bis-sulfones as cannabinoid-2 receptor ligands. , 2007, Bioorganic & medicinal chemistry letters.

[45]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[46]  A. Hamilton,et al.  Toward proteomimetics: terphenyl derivatives as structural and functional mimics of extended regions of an alpha-helix. , 2001, Journal of the American Chemical Society.

[47]  J. A. Grant,et al.  A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction. , 2005, Journal of medicinal chemistry.

[48]  Schmid,et al.  "Scaffold-Hopping" by Topological Pharmacophore Search: A Contribution to Virtual Screening. , 1999, Angewandte Chemie.

[49]  Hongmao Sun,et al.  A Universal Molecular Descriptor System for Prediction of LogP, LogS, LogBB, and Absorption , 2004, J. Chem. Inf. Model..

[50]  V. Hruby,et al.  Peptidomimetics, a synthetic tool of drug discovery. , 2008, Current opinion in chemical biology.

[51]  R. F. Reinoso,et al.  Discovery of potent and selective bicyclic A(2B) adenosine receptor antagonists via bioisosteric amide replacement. , 2010, Bioorganic & medicinal chemistry letters.

[52]  Xin Wen,et al.  BindingDB: a web-accessible database of experimentally determined protein–ligand binding affinities , 2006, Nucleic Acids Res..

[53]  J. Jenkins,et al.  A 3D similarity method for scaffold hopping from known drugs or natural ligands to new chemotypes. , 2004, Journal of medicinal chemistry.

[54]  R. Neubig,et al.  Design, synthesis and prostate cancer cell-based studies of analogs of the Rho/MKL1 transcriptional pathway inhibitor, CCG-1423. , 2010, Bioorganic & medicinal chemistry letters.

[55]  G. Schneider,et al.  Scaffold‐Hopping Potential of Ligand‐Based Similarity Concepts , 2006, ChemMedChem.

[56]  Gisbert Schneider,et al.  Scaffold‐Hopping: How Far Can You Jump? , 2006 .

[57]  L. Vassilev,et al.  MDM2 inhibitors for cancer therapy. , 2007, Trends in molecular medicine.

[58]  Matthias Rarey,et al.  Recore: A Fast and Versatile Method for Scaffold Hopping Based on Small Molecule Crystal Structure Conformations , 2007, J. Chem. Inf. Model..

[59]  Yigong Shi,et al.  Structure-activity based study of the Smac-binding pocket within the BIR3 domain of XIAP. , 2007, Bioorganic & medicinal chemistry.

[60]  Guido Koch,et al.  Novel 3-aminopyrazole inhibitors of MK-2 discovered by scaffold hopping strategy. , 2010, Bioorganic & medicinal chemistry letters.

[61]  C. Charriaut-Marlangue.  Apoptosis: a target for neuroprotection. , 2004, Therapie.

[62]  Fernando J. Álvarez-Franco,et al.  Modulating apoptosis as a target for effective therapy. , 2006, Molecular immunology.

[63]  Peter Willett,et al.  Unsupervised 3D Ring Template Searching as an Ideas Generator for Scaffold Hopping: Use of the LAMDA, RigFit, and Field-Based Similarity Search (FBSS) Methods , 2006, J. Chem. Inf. Model..

[64]  Robin Taylor,et al.  Research applications of the Cambridge Structural Database (CSD). , 2004, Chemical Society reviews.

[65]  E. Mylecharane.  5-HT2 receptor antagonists and migraine therapy , 2004, Journal of Neurology.

[66]  Ismael Zamora,et al.  SHOP: Receptor-Based Scaffold HOPping by GRID-Based Similarity Searches , 2009, J. Chem. Inf. Model..

[67]  G. Marshall,et al.  Conformational analysis of two cyclic analogs of angiotensin: implications for the biologically active conformation. , 1994, Biochemistry.

[68]  Paul A. Bartlett,et al.  CAVEAT: A program to facilitate the design of organic molecules , 1994, J. Comput. Aided Mol. Des..

[69]  N. Soter.  Urticaria: current therapy. , 1990, The Journal of allergy and clinical immunology.

[70]  Nathan Brown,et al.  On scaffolds and hopping in medicinal chemistry. , 2006, Mini reviews in medicinal chemistry.

[71]  K. Catt,et al.  International union of pharmacology. XXIII. The angiotensin II receptors. , 2000, Pharmacological reviews.

[72]  T. Unger,et al.  Angiotensin AT1/AT2 Receptors: Regulation, Signalling and Function , 2003, Blood pressure.

[73]  D. Johnston,et al.  Design and pharmacology of N-[(3R)-1,2,3,4-tetrahydroisoquinolinium- 3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)- 2-[4-cyclohexyl-4-(1H-1,2,4-triazol- 1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (1), a potent, selective, melanocortin subtype-4 receptor agonist. , 2002, Journal of medicinal chemistry.

[74]  David Fry,et al.  Molecular modeling of melanocortin receptors. , 2007, Current topics in medicinal chemistry.

[75]  Peter Ertl,et al.  Bioisosteric Replacement and Scaffold Hopping in Lead Generation and Optimization , 2010, Molecular informatics.

[76]  Minoru Ishikawa,et al.  Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry. , 2011, Journal of medicinal chemistry.

[77]  P. Furet,et al.  Identification of a new chemical class of potent angiogenesis inhibitors based on conformational considerations and database searching. , 2003, Bioorganic & medicinal chemistry letters.

[78]  Ian A. Watson,et al.  ErG: 2D Pharmacophore Descriptions for Scaffold Hopping , 2006, J. Chem. Inf. Model..

[79]  U. Koch,et al.  Novel P2-P4 macrocyclic inhibitors of HCV NS3/4A protease by P3 succinamide fragment depeptidization strategy. , 2010, Bioorganic & medicinal chemistry letters.

[80]  A. Naylor,et al.  Discovery of a novel indole series of EP1 receptor antagonists by scaffold hopping. , 2008, Bioorganic & medicinal chemistry letters.

[81]  G. Schneider,et al.  Scaffold architecture and pharmacophoric properties of natural products and trade drugs: application in the design of natural product-based combinatorial libraries. , 2001, Journal of combinatorial chemistry.

[82]  Anna Linusson,et al.  SHOP: scaffold HOPping by GRID-based similarity searches. , 2007, Journal of medicinal chemistry.

[83]  G. Hessler,et al.  The scaffold hopping potential of pharmacophores. , 2010, Drug discovery today. Technologies.

[84]  David C Fry,et al.  A predictive pharmacophore model of human melanocortin-4 receptor as derived from the solution structures of cyclic peptides. , 2004, Bioorganic & medicinal chemistry.

[85]  T. Yue,et al.  Apoptosis: a potential target for discovering novel therapies for cardiovascular diseases. , 1999, Current opinion in chemical biology.

[86]  J. Burbach,et al.  Conformation of the Core Sequence in Melanocortin Peptides Directs Selectivity for the Melanocortin MC3 and MC4 Receptors* , 1999, The Journal of Biological Chemistry.

[87]  Ajay,et al.  Kinase patent space visualization using chemical replacements. , 2006, Journal of medicinal chemistry.

[88]  William L. Smith,et al.  Coxibs interfere with the action of aspirin by binding tightly to one monomer of cyclooxygenase-1 , 2009, Proceedings of the National Academy of Sciences.

[89]  J. Bajorath,et al.  Chemical Substitutions That Introduce Activity Cliffs Across Different Compound Classes and Biological Targets , 2010, J. Chem. Inf. Model..

[90]  Youssef L Bennani,et al.  Drug discovery in the next decade: innovation needed ASAP. , 2012, Drug discovery today.

[91]  K. Das,et al.  Engineering ML-IAP to produce an extraordinarily potent caspase 9 inhibitor: implications for Smac-dependent anti-apoptotic activity of ML-IAP. , 2005, The Biochemical journal.

[92]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[93]  C. Welch,et al.  Design, synthesis, and biological activities of four angiotensin II receptor ligands with gamma-turn mimetics replacing amino acid residues 3-5. , 1997, Journal of medicinal chemistry.

[94]  Garret A. FitzGerald,et al.  COX-2 and beyond: approaches to prostaglandin inhibition in human disease , 2003, Nature Reviews Drug Discovery.

[95]  J C Reed,et al.  Mitochondria and apoptosis. , 1998, Science.

[96]  B. Kuhn,et al.  Intramolecular hydrogen bonding in medicinal chemistry. , 2010, Journal of medicinal chemistry.

[97]  Xiaodong Wang,et al.  Structural and biochemical basis of apoptotic activation by Smac/DIABLO , 2000, Nature.

[98]  W. Sneader.  Drug prototypes and their exploitation , 1996 .

[99]  C. Soto,et al.  Converting a peptide into a drug: strategies to improve stability and bioavailability. , 2002, Current medicinal chemistry.

[100]  Nicolas Moitessier,et al.  Constrained peptidomimetics reveal detailed geometric requirements of covalent prolyl oligopeptidase inhibitors. , 2009, Journal of medicinal chemistry.

[101]  R. Cramer,et al.  Prospective identification of biologically active structures by topomer shape similarity searching. , 1999, Journal of medicinal chemistry.

[102]  Adam Yasgar,et al.  Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[103]  Y. Martin,et al.  Do structurally similar molecules have similar biological activity? , 2002, Journal of medicinal chemistry.

[104]  G R Marshall,et al.  Three-dimensional recognition requirements for angiotensin agonists: a novel solution for an old problem. , 1993, Biochemical and biophysical research communications.

[105]  J. Andrew Grant,et al.  Molecular shape and electrostatics in the encoding of relevant chemical information , 2005, J. Comput. Aided Mol. Des..

[106]  R. Kurumbail,et al.  A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors. , 2001, The Biochemical journal.

[107]  P. Dubový,et al.  Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures — A short review , 2008, Pharmacology Biochemistry and Behavior.

[108]  C. Humblet,et al.  Escape from flatland: increasing saturation as an approach to improving clinical success. , 2009, Journal of medicinal chemistry.

[109]  Toshio Shimizu,et al.  Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors , 2010, Cancer Chemotherapy and Pharmacology.

[110]  G. Giaccone,et al.  Apoptosis: target of cancer therapy. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[111]  Evan Bolton,et al.  An overview of the PubChem BioAssay resource , 2009, Nucleic Acids Res..

[112]  Erinna F. Lee,et al.  Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family , 2007, Cell Death and Differentiation.

[113]  Ian A. Watson,et al.  Characteristic physical properties and structural fragments of marketed oral drugs. , 2004, Journal of medicinal chemistry.

[114]  Terry Walsh,et al.  Countering cooperative effects in protease inhibitors using constrained beta-strand-mimicking templates in focused combinatorial libraries. , 2004, Journal of medicinal chemistry.